![]() ![]() Texas Retina Associates (Dallas, TX): Gary Edd Fish, MD (PI) Hank A. Williams, MD (PI) Sara Beardsley, COA (VA/R) Steven Bennett, MD (O) Herbert Cantrill, MD (O) Carmen Chan-Tram, COA (VA/R) Holly Cheshier, CRA, COT, OCTC (OP) John Davies, MD (O) Sundeep Dev, MD (O) Julianne Enloe, CCRP, COA (CC) Gennaro Follano (OP/OCT) Peggy Gilbert, COA (VA/R) Jill Johnson, MD (O) Tori Jones, COA (OCT) Lisa Mayleben, COMT (CC/VA/R/OCT) Robert Mittra, MD (O) Martha Moos, COMT, OSA (VA/R) Ryan Neist, COMT (VA/R) Neal Oestreich, COT (CC) Polly Quiram, MD (O) Robert Ramsay, MD (O) Edwin Ryan, MD (O) Stephanie Schindeldecker, OA (VA/R) Trenise Steele, COA (VA) Jessica Tonsfeldt, AO (OP) Shelly Valardi, COT (VA/R). ![]() Comparison of Age-related Macular Degeneration Treatments Trials (CATT)Research Group: VitreoRetinal Surgery, PA (Edina, MN): David F. The funding organization had no role in the design or conduct of this research. Supported by R21EY02368 from National Eye Institute.Supported by cooperative agreements U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828 and R21EY023689 from the National Eye Institute, National Institutes of Health, and Department of Health and Human Services. Predominantly persistent intraretinal fluid through year 2 was independently associated with worse long-term VA and scar development. Predominantly persistent intraretinal fluid through year 1 was associated with worse long-term VA, but the relationship disappeared after adjustment for baseline predictors of VA. Conclusions: Approximately one quarter of eyes had PP-IRF through year 2. Predominantly persistent intraretinal fluid through year 2 was associated with a higher 2-year risk of scar development (adjusted hazard ratio = 1.49 P = 0.03). 8.1 P = 0.01) as well as worse adjusted 2-year mean VA scores (63.0 vs. Predominantly persistent intraretinal fluid through year 2 was associated with worse adjusted 1-year mean VA scores (64.8 vs. ![]() When eyes with PP-IRF through year 1 were compared with those without PP-IRF, the mean 1-year VA score was 62.4 and 68.5, respectively (P = 0.002), and was 65.0 and 67.4, respectively (P = 0.13), after adjustment. Results: Among 363 eyes with baseline IRF, 108 (29.8%) had PP-IRF through year 1 and 95 (26.1%) had PP-IRF through year 2. Main Outcome Measures: Predominantly persistent intraretinal fluid through week 12, year 1, and year 2 VA score and VA change and scar development at year 2. Furthermore, outcomes were adjusted for concomitant predominantly persistent subretinal fluid. Adjusted mean VA scores and changes from the baseline were also calculated using the linear regression analysis to account for baseline patient features identified as predictors of VA in previous CATT studies. Among eyes with baseline IRF, the mean VA scores (letters) and changes from the baseline were compared between eyes with and those without PP-IRF. Predominantly persistent intraretinal fluid through week 12, year 1, and year 2 was defined as the presence of IRF at the baseline and in ≥ 80% of follow-up visits. Methods: The presence of intraretinal fluid (IRF) on OCT scans was assessed at baseline and monthly follow-up visits by Duke OCT Reading Center. Participants: Participants in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) assigned to PRN treatment. Design: Cohort within a randomized clinical trial. Purpose: To describe predominantly persistent intraretinal fluid (PP-IRF) and its association with visual acuity (VA) and retinal anatomic findings at long-term follow-up in eyes treated with pro re nata (PRN) ranibizumab or bevacizumab for neovascular age-related macular degeneration. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |